Effects of activated carbon N‑acetylcysteine sustained‑release microcapsule on dipeptidyl peptidase IV expression in young rats with non‑alcoholic fatty liver disease

Zhou,Hongping; Shi,Tingting; Yan,Jun; Chen,Xiaojin; Liao,Li; Zhao,Shiyong; Fang,Hongying; Zhuang,Rangxiao

doi:10.3892/etm.2017.5128

Effects of activated carbon N‑acetylcysteine sustained‑release microcapsule on dipeptidyl peptidase IV expression in young rats with non‑alcoholic fatty liver disease

Authors:
- Hongping Zhou
- Tingting Shi
- Jun Yan
- Xiaojin Chen
- Li Liao
- Shiyong Zhao
- Hongying Fang
- Rangxiao Zhuang
View Affiliations

Affiliations: Department of Pharmacy, Hangzhou Children's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Department of Pharmaceutical Preparation, The Xixi Hospital of Hangzhou Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310023, P.R. China
Published online on: September 19, 2017 https://doi.org/10.3892/etm.2017.5128
Pages: 4737-4744
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) in children has become the most common liver disease influencing adolescent health and one of the most influencing chronic liver diseases among children in Chinese wealthy families, particularly in coastal regions. However, the medicine available for the treatment of NAFLD is deficient. In order to solve this problem, our team studied the activated carbon N‑acetylcysteine (NAC) sustained‑release microcapsule, which improves the oxidation resistance, bioavailability and drug stability of acetylcysteine and reduces toxic and side effects. In addition, it accords with the characteristics of medication in infants and children. The present study mainly discusses whether the activated carbon NAC sustained‑release microcapsule has effects on dipeptidyl peptidase IV (DPPIV) activity and protein in young rats with NAFLD, and whether it has the effect of an DPPIV inhibitor, hoping to provide new thoughts and methods with respect of basic studies on young rats with NAFLD/non‑alcoholic steatohepatitis.

View Figures

View References

1	Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE and Kowdley KV: Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology. 55:1103–1111. 2012. View Article : Google Scholar : PubMed/NCBI
2	Fan JG: Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 28 Suppl 1:S11–S17. 2013. View Article : Google Scholar
3	Fan JG and Zeng MD: Fatty liver disease. Version 2. Beijing: People's Medical Publishing House 20; 2013
4	Farrell GC, McCullough AJ and Day CP: Non-Alcoholic Fatty Liver Disease: A Practical Guide. Wiley-Blackwell; Oxford: pp. 2162013
5	Loomba R, Sirlin CB, Schwimmer JB and Lavine JE: Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 50:1282–1293. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gorrell MD: Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 108:277–292. 2005. View Article : Google Scholar : PubMed/NCBI
7	Fimeisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K and Somogyi A: Seram dipeptidyl peptidase-4 activity in insulin resistant patients with nonalcoholic fatty liver disease: A novel liver disease biomarker. PLoS One. 5:e122262010. View Article : Google Scholar : PubMed/NCBI
8	Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR, et al: CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronin HCV genotype 4 infected patients. Cytokine. 63:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chielle Ottobelli E, de Souza WM, da Silva TP, Moresco RN and Moretto MB: Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem. 49:548–553. 2016. View Article : Google Scholar : PubMed/NCBI
10	Machado MV, Kruger L, Jewell ML, Michelotti GA, Pereira Tde A, Xie G, Moylan CA and Diehl AM: Vitamin B5 and N-acetylcysteine in nonalcoholic steatohepatitis: A preclinical study in a dietary mouse model. Dig Dis Sci. 61:137–148. 2016. View Article : Google Scholar : PubMed/NCBI
11	Qu QL, Zhang YG, Yang LZ and Sun L: Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 28:257–260. 2006.(In Chinese). PubMed/NCBI
12	Wang FG, Zhuang RX, Xi JJ, Fang HY and Gao JQ: Preparation and distribution in mice of acetylcysteine nanoparticles. Zhongguo Yiyao Gongye Zazhi. 43:572–576. 2012.(In Chinese).
13	Wang FG, Shen YQ, Zhuang RX, Xi JJ and Fang HY: Study on preparation of acetylcysteine nanoparticles. Strait Pharmaceut J. 25:15–17. 2013.
14	Jia L, Wang J, Shi JP, Wang F, Gang H, Zhu M and Lou G: The effect of N-acetylcysteine nano-carbon on anti-oxidative capacity in non-alcoholic steatohepatitis rats. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 28:4–6. 2014.(In Chinese).
15	Fang HY, Zhang RX, Xi JJ, Sun JJ, Shao YD, Si ZZ, Pan XW and Wang FG: Role of treatment on liver fibrosis of activated carbon N-acetylcysteine microcapsule. Zhong Guo Lin Chuang Yao Li Xue Yu Zhi Liao Xue Bian Ji Bu. 20:976–980. 2015.(In Chinese).
16	Pei Z, Li X, Longenecker K, von Geldern TW, Wiedeman PE, Lubben TH, Zinker BA, Stewart K, Ballaron SJ, Stashko MA, et al: Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV Inhibitors. J Med Chem. 49:3520–3535. 2006. View Article : Google Scholar : PubMed/NCBI
17	Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 89:2637–2645. 2000. View Article : Google Scholar : PubMed/NCBI
18	Lavine JE and Schwimmer JB: Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis. 8(549–558): viii–ix. 2004.
19	Fraser A, Longnecker MP and Lawlor DA: Prevalence of elevated alanine aminotrasferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology. 133:1814–1820. 2007. View Article : Google Scholar : PubMed/NCBI
20	Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C and Behling C: Prevalence of fatty liver in children and adolescents. Pediatric. 118:1388–1393. 2006. View Article : Google Scholar
21	Kohli R, Boyd T, Lake K, Dietrich K, Nicholas L, Balistreri WF, Ebach D, Shashidhar H and Xanthakos SA: Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr. 50:453–456. 2010.PubMed/NCBI
22	Holterman A, Gurria J, Tanpure S and DiSomma N: Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Semin Pediatr Surg. 23:49–57. 2014. View Article : Google Scholar : PubMed/NCBI
23	Alterio A, Alisi A, Liccardo D and Nobili V: Non-alcoholic fatty liver and metabolic syndrome in children: A vicious circle. Horm Res Paediatr. 82:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ozhan B, Ersoy B, Kiremitci S, Ozkol M and Taneli F: Insulin sensitivity indices: Fasting versus glucose-stimulated indices in pediatric non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 19:3450–3458. 2015.PubMed/NCBI
25	Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA and Fraser A: The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One. 10:e01409082015. View Article : Google Scholar : PubMed/NCBI
26	Jogo R, Ness AR, Emmett P, Mattocks C, Jones L and Riddoch CJ: Obesogenic diet and physical activity: Independent or associated behaviours in adolescents? Public Health Nutr. 13:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
27	Monteiro PA, Antunes Bde M, Silveira LS, Christofaro DG, Fernandes RA and Junior Freitas IF: Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatr. 14:252014. View Article : Google Scholar : PubMed/NCBI
28	Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, Sartorelli MR, Comparcola D, Piemonte F and Nobili V: Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut. 57:1283–1287. 2008. View Article : Google Scholar : PubMed/NCBI
29	Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middleton MS and Sirlin CB: Heritability of nonalcoholic fatty liver disease. Gastroenterology. 136:1585–1592. 2009. View Article : Google Scholar : PubMed/NCBI
30	Alisi A and Nobili V: Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. Nutrition. 28:722–726. 2012. View Article : Google Scholar : PubMed/NCBI
31	Black LJ, Jacoby P, She Ping-Delfos WC, Mori TA, Beilin LJ, Olynyk JK, Ayonrinde OT, Huang RC, Holt PG, Hart PH, et al: Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol. 29:1215–1222. 2014. View Article : Google Scholar : PubMed/NCBI
32	Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA and Knipp GT: Summary of the national institute of child health and human development-best pharmaceuticals for children act pediatric formulation initiatives workshop-pediatric biopharmaceutics classification system working group. Clin Ther. 11:S11–S24. 2012. View Article : Google Scholar
33	Ma LX, Liu X, Yan GQ, et al: Problems and thoughts on children drug use. Chin Hospitals. 16:45–46. 2012.
34	Hu N: Present situation and development strategy of paediatric formulations. Med Sci. 1:2392015.
35	Drucker DJ and Nauck MA: The incretin system: Glucagons-like peptide-l receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diahetes. Lancet. 368:1696–1705. 2006. View Article : Google Scholar : PubMed/NCBI
36	Holst JJ: Glucagon-like peptide-1: From extract to agent. The claude bernard lecture, 2005. Diabetologia. 49:253–260. 2006. View Article : Google Scholar : PubMed/NCBI
37	Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E and Tatar G: Dipeptidyl peptidaseIV (DPPIV) in NASH patients. Ann Hepatol. 6:242–250. 2007.PubMed/NCBI
38	Han Q: The study of the relationship between DPPIV and fatty liver disease inobese children and young rats. Tianjin Med Uni. 5:2011.
39	Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, et al: Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 60:1246–1257. 2011. View Article : Google Scholar : PubMed/NCBI
40	Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C and Duman DG: Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 75:240–244. 2012.PubMed/NCBI